Core Insights - Castle Biosciences reported Q2 2025 revenue of $86 million, a slight decrease from $87 million in Q2 2024, while total test reports for core revenue drivers increased by 33% year-over-year [1][4] - The company raised its full-year 2025 revenue guidance to a range of $310-320 million from the previous range of $287-297 million, reflecting strong performance in its core tests [7] Financial Highlights - Q2 2025 revenues were $86.2 million, compared to $87.0 million in Q2 2024, with adjusted revenues of $86.2 million, slightly down from $86.6 million in the same period last year [4] - Total test reports delivered in Q2 2025 were 26,574, a 6% increase from 25,102 in Q2 2024 [4] - Gross margin for Q2 2025 was 77%, with an adjusted gross margin of 80%, compared to 81% and 83% in Q2 2024, respectively [4] - Net cash provided by operations was $20.8 million, down from $24.0 million in Q2 2024 [4] Operational Highlights - The company delivered 9,981 DecisionDx-Melanoma test reports in Q2 2025, up from 9,585 in Q2 2024, and 9,170 TissueCypher Barrett's Esophagus test reports, significantly up from 4,782 in the same period last year [4] - The DecisionDx-SCC test reports delivered were 4,762, compared to 4,277 in Q2 2024, despite the impact of the Novitas local coverage determination [4] - The company discontinued its IDgenetix test offering in May 2025, which affected test report volumes [4] Strategic Developments - Castle Biosciences completed the acquisition of Previse and announced a collaboration with SciBase, aimed at enhancing its gastrointestinal offerings and developing new diagnostic tests [3][10] - The company is focused on executing its current test portfolio while investing in future growth initiatives [3] Market Position and Future Outlook - The company anticipates continued growth in test volumes and revenue, supported by the clinical value of its tests [2] - The DecisionDx-Melanoma test has received Breakthrough Device designation from the FDA, which may enhance its market position [13] - The company aims to create a multiomics approach for improved patient care in Barrett's esophagus through its acquisition of Previse [10]

Company Overview - Castle Biosciences, Inc. is a diagnostics company focused on improving health through innovative tests that guide patient care [3] - The company aims to transform disease management by prioritizing patients, clinicians, employees, and investors [3] Upcoming Presentation - The executive management of Castle Biosciences is scheduled to present a company overview at the Canaccord Genuity 45 Annual Growth Conference on August 12, 2025, at 12:30 p.m. Eastern time [1] - A live audio webcast of the presentation will be available on the company's website, with a replay accessible after the live broadcast [2] Product Portfolio - Castle's current portfolio includes tests for skin cancers, Barrett's esophagus, and uveal melanoma [4] - The company is actively developing tests for diseases with high clinical need, including a test for guiding systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment [4]

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Castle Biosciences, Inc. due to lower revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected on August 4, with a consensus estimate of a quarterly loss of $0.51 per share, reflecting a year-over-year change of -264.5% [3]. - Revenues are projected to be $73.89 million, down 15.1% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 26% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictor for positive readings [9][10]. - Castle Biosciences currently holds a Zacks Rank of 4, making it challenging to predict an earnings beat [12][13]. Historical Performance - In the last reported quarter, Castle Biosciences was expected to post a loss of $0.08 per share but actually reported a loss of -$0.20, resulting in a surprise of -150.00% [14]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [15]. Industry Comparison - Moderna, another player in the Zacks Medical - Biomedical and Genetics industry, is expected to report a loss of $2.99 per share, with revenues projected at $127.17 million, down 47.2% year-over-year [19][20]. - Moderna's consensus EPS estimate has been revised 1.4% lower, but it has a positive Earnings ESP of +7.22% and a Zacks Rank of 3, indicating a likelihood of beating the consensus estimate [20][21].

Core Insights - Castle Biosciences' CEO Derek Maetzold has been recognized as a 2025 Most Admired CEO by the Houston Business Journal for his exceptional leadership and contributions to the community [3][4] - The award highlights the importance of financial stewardship and fostering inclusive workplace cultures, which are key aspects of Maetzold's leadership approach [3][4] Company Overview - Castle Biosciences (Nasdaq: CSTL) is a diagnostics company focused on improving health through innovative tests that guide patient care [5] - The company aims to transform disease management by prioritizing the needs of patients, clinicians, employees, and investors [5] Product Portfolio - Castle's current portfolio includes diagnostic tests for skin cancers, Barrett's esophagus, and uveal melanoma [6] - The company is also engaged in research and development for additional tests addressing high clinical needs, including a test for guiding systemic therapy selection for patients with moderate-to-severe atopic dermatitis [6]

Core Insights - Castle Biosciences, Inc. announced that its DecisionDx-Melanoma test received Breakthrough Device designation from the FDA, aimed at improving patient care for those diagnosed with stage I-III cutaneous melanoma [1][3] Company Overview - Castle Biosciences is a diagnostics company focused on innovative tests that guide patient care, with a mission to transform disease management by prioritizing patients, clinicians, employees, and investors [5] - The company has a portfolio that includes tests for skin cancers, Barrett's esophagus, and uveal melanoma, and is engaged in R&D for additional tests in high clinical need areas [6] Product Details - DecisionDx-Melanoma is a gene expression profile test that assesses a patient's risk of sentinel lymph node positivity and melanoma recurrence/metastasis, integrating tumor biology with clinical factors [4] - The test has been validated through over 10,000 patient samples and is supported by more than 50 peer-reviewed studies, demonstrating its clinical value and association with improved patient survival [4] - As of March 31, 2025, DecisionDx-Melanoma has been ordered over 200,000 times for patients diagnosed with cutaneous melanoma [4]

Core Insights - Castle Biosciences, Inc. has received multiple awards in the 2025 Top Workplaces program, including a third consecutive national Healthcare Industry Top Workplaces award, ranking third in its size category, and a fourth consecutive regional Arizona Top Workplaces award [1][2] - The company has also been recognized for its Culture Excellence in various categories such as Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership, and Purpose & Values [1][2] Company Overview - Castle Biosciences is a leading diagnostics company focused on improving health through innovative tests that guide patient care, with a mission to transform disease management by prioritizing patients, clinicians, employees, and investors [3] - The company's current portfolio includes tests for skin cancers, Barrett's esophagus, and uveal melanoma, along with ongoing research and development for additional tests addressing high clinical needs [4] Awards and Recognition - The Top Workplaces awards are based on anonymous employee feedback collected through a third-party survey, which evaluates workplace experience and culture themes indicative of successful organizations [2] - Castle's awards in specific categories highlight its commitment to fostering a people-first culture, which is seen as a catalyst for innovation and impact [2][5]

FRIENDSWOOD, Texas, July 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended June 30, 2025, after the close of market on Monday, Aug. 4, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast Details DecisionDx-Mela ...

Core Points - Castle Biosciences, Inc. granted restricted stock units (RSUs) to 66 employees, covering a total of 135,978 shares of common stock as part of their employment inducement [1] - The RSUs will vest over a four-year period, with 25% vesting on the first anniversary and the remaining shares vesting annually in three equal installments, contingent on continued service [2] - Castle Biosciences focuses on innovative diagnostic tests that guide patient care, with a portfolio that includes tests for skin cancers, Barrett's esophagus, and uveal melanoma [3][4] Company Overview - Castle Biosciences aims to transform disease management by prioritizing patients, clinicians, employees, and investors [3] - The company is actively engaged in research and development for tests addressing high clinical needs, including a test for guiding systemic therapy selection for patients with moderate-to-severe atopic dermatitis [4]

Core Insights - Castle Biosciences has entered a collaboration and license agreement with SciBase to develop a diagnostic test aimed at predicting flares in patients with atopic dermatitis [1][2][3] - The collaboration targets a potential market of up to 24 million patients in the United States suffering from atopic dermatitis, many of whom experience flares while on maintenance treatment [2][3] - SciBase's technology will be utilized to enhance patient care in dermatology, complementing Castle's existing portfolio of tests for skin cancers and other dermatological conditions [3][5] Company Overview - Castle Biosciences is a diagnostics company focused on innovative tests that guide patient care, with a mission to transform disease management [4] - The company's current portfolio includes tests for skin cancers, Barrett's esophagus, and uveal melanoma, along with ongoing research for additional tests in high clinical need areas [5] Collaboration Details - Under the agreement, both companies will explore various clinical indications related to dermatologic diseases, with SciBase focusing on the EU, Switzerland, UAE, Japan, and South Korea, while Castle will target North America [3] - SciBase will receive a single-digit royalty on Castle's gross margin and a low double-digit percentage markup on product sales, along with a milestone payment of 5 million USD when Castle's sales reach 50 million USD annually [3]

Group 1 - Castle Biosciences, Inc. will participate in a panel discussion at the 2025 BIO International Convention, focusing on the challenges faced by precision medicine companies in commercializing innovative diagnostic tests [1][2] - The panel titled "Advancing Innovative Risk-Stratification Tests That Impact Treatment Pathway Decisions: Challenges in Overcoming Barriers to Entry" is scheduled for June 17, 2025, from 11 a.m. to 12 p.m. Eastern Time [2] - The session will be moderated by Michael Ryan, J.D., and will include industry leaders discussing strategies for navigating market complexities while improving patient care [2][8] Group 2 - Castle Biosciences is a leading diagnostics company that aims to improve health through innovative tests that guide patient care [5] - The company's current portfolio includes tests for skin cancers, Barrett's esophagus, and uveal melanoma, with ongoing research for additional tests in high clinical need areas [6] - Castle Biosciences emphasizes a patient-first approach in transforming disease management, focusing on the needs of patients, clinicians, employees, and investors [5][6]